| General Information | |
|---|---|
| ZINC ID | ZINC000040899603 |
| Molecular Weight (Da) | 506 |
| SMILES | O=C(Cn1nc(-c2ccc(Cl)cc2Cl)c(-c2ccc(Cl)cc2Cl)n1)NCc1ccccc1 |
| Molecular Formula | C23Cl4N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 129.734 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| LogP | 7.025 |
| Activity (Ki) in nM | 67.6083 |
| Polar Surface Area (PSA) | 59.81 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.016 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 23 |
| Fraction csp3 | 0.09 |
| Ilogp | 3.69 |
| Xlogp3 | 7.02 |
| Wlogp | 6.39 |
| Mlogp | 4.19 |
| Silicos-it log p | 6.42 |
| Consensus log p | 5.54 |
| Esol log s | -7.47 |
| Esol solubility (mg/ml) | 0.0000171 |
| Esol solubility (mol/l) | 3.38E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.09 |
| Ali solubility (mg/ml) | 0.0000041 |
| Ali solubility (mol/l) | 8.09E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.68 |
| Silicos-it solubility (mg/ml) | 1.06E-08 |
| Silicos-it solubility (mol/l) | 2.10E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.4 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.32 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.891 |
| Logd | 4.19 |
| Logp | 6.157 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 101.06% |
| Vdss | 1.278 |
| Fu | 1.24% |
| Cyp1a2-inh | 0.689 |
| Cyp1a2-sub | 0.152 |
| Cyp2c19-inh | 0.952 |
| Cyp2c19-sub | 0.075 |
| Cl | 10.267 |
| T12 | 0.009 |
| H-ht | 0.241 |
| Dili | 0.983 |
| Roa | 0.043 |
| Fdamdd | 0.378 |
| Skinsen | 0.041 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.006 |
| Bcf | 3.534 |
| Igc50 | 5.038 |
| Lc50 | 6.938 |
| Lc50dm | 5.608 |
| Nr-ar | 0.014 |
| Nr-ar-lbd | 0.023 |
| Nr-ahr | 0.842 |
| Nr-aromatase | 0.266 |
| Nr-er | 0.493 |
| Nr-er-lbd | 0.006 |
| Nr-ppar-gamma | 0.182 |
| Sr-are | 0.87 |
| Sr-atad5 | 0.095 |
| Sr-hse | 0.007 |
| Sr-mmp | 0.773 |
| Sr-p53 | 0.673 |
| Vol | 454.122 |
| Dense | 1.11 |
| Flex | 0.292 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.323 |
| Synth | 2.366 |
| Fsp3 | 0.087 |
| Mce-18 | 23 |
| Natural product-likeness | -1.212 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |